J B Chemicals and Pharmaceuticals (JB Chemicals), a leading player in the Indian pharmaceutical industry, has announced significant changes to its board composition and leadership team, signaling a strong commitment to sustained growth and corporate governance.

CEO Re-appointment Signals Continuity in Leadership

JB Chemicals has re-appointed Nikhil Chopra as Chief Executive Officer and Whole-time Director for a five-year term starting October 5, 2025. Under Chopra's stewardship, the company has achieved remarkable growth, outpacing the industry average with a 16% growth rate compared to the sector's 10%.

Chopra's tenure has been marked by significant milestones, including:

• Nearly doubling the company's revenue to over INR 3,000.00 crore in FY23
• Positioning JB Chemicals as one of the fastest-growing companies among the top 25 in the pharmaceutical industry for two consecutive years
• Elevating the company to become one of the top 10 players in cardiology therapy in the Indian pharmaceutical market
• Establishing JB Chemicals as a leader in the hypertension segment

Board Reinforcement with Experienced Directors

The company has also made strategic additions to its board, appointing two new independent directors:

1. Richa Arora: Appointed for a five-year term effective July 10, 2025. Arora brings over three decades of experience in governance, strategy, business transformation, and marketing. Her expertise spans across various sectors, including FMCG and technology.

2. Ashwani Kumar Puri: Set to join the board for a five-year term starting May 14, 2025. Puri, a Chartered Accountant with over 33 years of experience at PwC, brings valuable insights in advisory services and corporate governance.

Continuity in Independent Oversight

In addition to the new appointments, JB Chemicals has re-appointed Sumit Bose as an independent director for a second five-year term, effective August 31, 2025. Bose, a former member of the Indian Administrative Services, has served in various capacities in the Government of India, including as Union Finance Secretary.

Annual General Meeting Highlights

The company held its 49th Annual General Meeting on August 6, 2025, via video conference, where these appointments were approved. The meeting also saw the re-appointment of M/s. Deloitte Haskins & Sells LLP as Statutory Auditors and the appointment of M/s. N L Bhatia & Associates as Secretarial Auditors for a five-year term.

Looking Ahead

These strategic appointments and re-elections reflect JB Chemicals' commitment to maintaining strong leadership and enhancing its board's expertise. With a blend of continuity and fresh perspectives, the company appears well-positioned to build on its recent successes and drive further growth in the competitive pharmaceutical landscape.

As JB Chemicals continues to strengthen its market position, particularly in cardiology and hypertension segments, investors and industry observers will be keenly watching how these leadership changes translate into sustained performance and innovation in the coming years.

J B Chemicals and Pharmaceuticals has reported strong financial results for the first quarter, demonstrating robust growth across key metrics and setting new benchmarks in profitability.

Revenue Growth and Financial Highlights

The company delivered quarterly revenues of INR 1,094.00 crore, marking a 9% year-on-year growth. The domestic business, which constitutes 62% of the total revenue, grew by an impressive 14% to INR 678.00 crore. International operations, accounting for the remaining 38%, increased by 2% to INR 416.00 crore.

J.B. Chemicals achieved record operating EBITDA margins of 30.2%, up 120 basis points year-on-year. The operating EBITDA (excluding ESOP and one-off charges) rose 13% to INR 330.00 crore. Gross margins expanded significantly to 68.3% from 66.2% in the previous year, reflecting the company's focus on cost optimization and favorable business mix.

Net profit for the quarter grew by 14% to INR 202.00 crore, underscoring the company's ability to translate top-line growth into bottom-line results.

Domestic Business Performance

The domestic business outperformed the industry, growing at 13% compared to the industry's 9% growth, as per IQVIA data. The chronic portfolio continued its strong performance with a 15% year-on-year growth, while the acute business increased by 12%.

Key brand performances were particularly noteworthy:

• The Sporlac franchise reached INR 146.00 crore, more than doubling from INR 70.00 crore in June 2022.
• Azmarda, a key brand in the heart failure segment, is now a INR 75.00 crore brand.
• The Razel franchise crossed the INR 100.00 crore mark, up from INR 69.00 crore in June 2023.
• The ophthalmology portfolio delivered a robust 19% year-on-year growth.

International Business and CDMO Segment

The international business saw modest growth, primarily driven by the CDMO (Contract Development and Manufacturing Organization) segment. The CDMO business grew by 8% year-on-year to INR 115.00 crore, with new product launches in Asia Pacific and EU markets.

Strategic Developments

In a significant development, Torrent Pharma announced plans to acquire a controlling stake in J.B. Chemicals for INR 11,917.00 crore, to be followed by a merger. The transaction, subject to regulatory approvals, includes a tender offer at INR 1,639.18 per share.

Management Commentary

Nikhil Chopra, CEO and Whole-Time Director of J.B. Chemicals, commented on the results: "J.B.'s operating momentum continues to impress. The business is amongst the fastest growing in India within the Indian pharma market. We remain focused on driving top-line momentum, cost optimization, and organizational efficiencies."

Future Outlook

The company maintains a positive outlook, expecting continued growth in its domestic and CDMO businesses. Management has guided for CDMO growth between 12% to 14% for the year, with an average run rate of INR 120.00 crore in the first half, increasing to INR 130.00 crore in the second half.

J.B. Chemicals' strong performance demonstrates its resilience and growth potential in a competitive pharmaceutical market. With its focus on key brands, expansion in chronic and international CDMO segments, and strategic initiatives, the company appears well-positioned for sustained growth in the coming quarters.